Massachusetts is a thriving hub for biotechnology, known for its innovation in the life sciences. Companies in this sector range from small startups to established firms focusing on creating new medicines and therapies. Many organizations specialize in areas like drug development, genetic engineering, and immunotherapies, catering to pressing medical needs. Data suggests that continued investment in R&D will drive the industry's growth, particularly as companies respond to global health challenges. Insights indicate a trend towards collaboration between biotech firms and academic institutions, fostering inventive solutions to improve patient care and outcomes.

This list features 24 biotechnology companies situated across Massachusetts. Ranging in size from small teams to larger entities, these firms have been founded between 1984 and 2021. They specialize in various scientific fields, and many are clustered in hubs like Boston and Cambridge. Offering everything from therapeutic solutions and drug development services to advanced platforms in biotechnology, these organizations illustrate the state's robust presence in the biotech landscape.

Discover more about the top biotechnology companies in Massachusetts.

Top 24 Biotechnology Companies in Massachusetts

1. Sanyou Biopharmaceuticals Co., Ltd.

• Website: sanyoubio.com
• Ownership type: Private Equity
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Latest funding: Series B, August 2022
• Founded year: 2015
• Headcount: 201-500
• LinkedIn: sanyou-biopharmaceuticals-co-ltd

Sanyou Biopharmaceuticals Co., Ltd., founded in 2015 and based in Cambridge, Massachusetts, is a private equity-backed biopharmaceutical company. The firm specializes in the research and development of innovative biological drugs, providing a range of services that include integrated R&D platforms, antibody development, and protein production. Their primary clientele consists of pharmaceutical companies and research institutions that seek advanced solutions for drug development. Sanyou operates on a global scale, with multiple locations in the United States and China, which enhances their ability to serve a broad market. The company is committed to advancing the field of biotechnology through its focus on innovative drug development and high-quality production services.

2. Third Rock Ventures

• Website: thirdrockventures.com
• Ownership type: Private
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 98%, Other 2%
• Founded year: 2007
• Headcount: 51-200
• LinkedIn: third-rock-ventures

Third Rock Ventures, founded in 2007 and based in Boston, Massachusetts, is a private venture capital firm dedicated to the biotechnology and life sciences sectors. The firm focuses on creating and supporting innovative companies that aim to develop transformative therapies for serious diseases. Their portfolio features a range of companies, including Candid Therapeutics, which targets autoimmune diseases, and Marea Therapeutics, which is developing treatments for cardiometabolic conditions. Third Rock Ventures is committed to addressing significant unmet medical needs and has established a reputation for fostering a culture of innovation and operational excellence within its portfolio companies. With a team of experienced professionals, they actively engage in the biotechnology ecosystem, helping to translate scientific advancements into viable healthcare solutions.

3. Atlas Venture

• Website: atlasventure.com
• Ownership type: Private
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: September 2015
• Founded year: 1984
• Headcount: 11-50
• LinkedIn: atlas-venture

Atlas Venture is a biotechnology investment firm based in Cambridge, Massachusetts, founded in 1984. The firm specializes in building breakthrough biotech companies by collaborating with life science entrepreneurs. Atlas Venture provides not only capital but also essential resources to help these companies commercialize their scientific advancements. Over the years, they have launched more than 70 startups and have been involved in the development of over 25 medicines through their portfolio companies. Their investment strategy focuses on identifying transformative innovations in the biotech sector, particularly in areas such as gene therapy, RNA-based drugs, and precision oncology. Atlas Venture's commitment to fostering a collaborative and patient-centric culture underscores their role in the biotechnology industry, making them a significant player in the field.

4. Nimbus Therapeutics

• Website: nimbustx.com
• Ownership type: Venture Capital
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $210.0M, September 2023
• Founded year: 2009
• Headcount: 51-200
• LinkedIn: nimbus-therapeutics

Nimbus Therapeutics, founded in 2009 and based in Boston, Massachusetts, is a biotechnology firm dedicated to the discovery and development of small molecule therapeutics. The company specializes in tackling complex diseases, particularly in the fields of immunology, oncology, and metabolism. By utilizing advanced drug discovery techniques, Nimbus aims to create innovative treatment solutions that can significantly impact patient care. Their approach involves a collaborative structure-based drug discovery engine, which leverages cutting-edge technologies and expertise in computational chemistry and structural biology. This enables them to identify and drug targets that are often challenging for other companies. With a workforce of around 110 employees, Nimbus Therapeutics has established itself as a notable entity in the biotechnology sector. The company has recently secured $210 million in funding, reflecting strong investor interest and support for their mission to develop breakthrough medicines.

5. Prilenia

• Website: prilenia.com
• Ownership type: Venture Capital
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 41%, Israel 30%, Netherlands 12%, Other 16%
• Latest funding: Series B, $43.0M, November 2021
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: prilenia

Prilenia Therapeutics, founded in 2018 and based in Boston, Massachusetts, is a biotechnology company dedicated to developing novel therapeutics for neurodegenerative diseases, including Huntington's disease and amyotrophic lateral sclerosis (ALS). The company is currently advancing its investigational drug, pridopidine, which is a selective sigma-1 receptor agonist. This drug is designed to slow disease progression and has shown promise in clinical studies. Prilenia has a global presence, with operations in the United States, Israel, the Netherlands, Germany, and Spain. The company has successfully raised $43 million in its Series B funding round in November 2021, which underscores its potential and the interest of investors in its mission to provide hope to patients and families affected by these debilitating conditions. Prilenia is committed to scientific excellence and patient care, actively engaging in clinical research to bring new treatment options to market.

6. Generate:Biomedicines

• Website: generatebiomedicines.com
• Ownership type: Venture Capital
• Headquarters: Somerville, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: December 2024
• Founded year: 2018
• Headcount: 201-500
• LinkedIn: generate-biomedicines

Generate:Biomedicines, based in Somerville, Massachusetts, is a biotechnology firm that specializes in the development of innovative protein therapeutics through generative biology. Founded in 2018, the company utilizes advanced machine learning and biological engineering techniques to create novel medicines aimed at addressing unmet medical needs in the pharmaceutical and healthcare sectors. Their proprietary platform, known as The Generate Platform, allows for the rapid generation of therapeutic proteins, significantly enhancing the speed and success rates of drug discovery. Recently, Generate:Biomedicines announced a multi-target collaboration with Novartis, which highlights their active role in the industry and the potential for significant financial returns through performance-based milestones. The company has generated over 42,000 proteins and continues to expand its capabilities, making it a notable player in the biotechnology field.

7. Jounce Therapeutics, Inc.

• Website: jouncetx.com
• Ownership type: Corporate
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $1.9M, March 2023
• Founded year: 2013
• Headcount: 51-200
• LinkedIn: jounce-therapeutics

Jounce Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2013. The company focuses on developing pharmaceutical solutions and has recently acquired Theseus Pharmaceuticals, which enhances its position in the drug development arena. Jounce Therapeutics primarily serves businesses within the biotechnology and pharmaceutical sectors, indicating a strong alignment with industry needs. The company has a workforce of approximately 51-200 employees and has secured funding of $1,850,000 in March 2023, reflecting its active engagement in advancing its projects and initiatives.

8. Vedanta Biosciences, Inc.

• Website: vedantabio.com
• Ownership type: Venture Capital
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 99%, Other 1%
• Latest funding: Other (Grant), $3.9M, April 2024
• Founded year: 2010
• Headcount: 51-200
• LinkedIn: vedanta-biosciences-inc-

Vedanta Biosciences, Inc., founded in 2010 and based in Cambridge, Massachusetts, is a biotechnology firm dedicated to developing microbiome-based therapeutics aimed at treating gastrointestinal diseases. The company is pioneering the use of defined bacterial consortia to restore gut health and combat conditions such as Clostridium difficile infections. Their pipeline includes several promising drug candidates, notably VE303, VE202, and VE707, which are currently in various stages of clinical trials. Vedanta has received funding to support its research initiatives, including a recent grant of $3.9 million aimed at advancing its VE707 program, which targets multi-drug resistant infections. The company’s commitment to rigorous scientific research and its innovative approach to drug development underscore its role in the biotechnology sector.

9. Alzheon, Inc. | Preserving Future Memories

• Website: alzheon.com
• Ownership type: Venture Capital
• Headquarters: Framingham, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 93%, Czech Republic 7%
• Latest funding: Series E-K, $100.0M, June 2024
• Founded year: 2013
• Headcount: 11-50
• LinkedIn: alzheon

Alzheon, Inc., based in Framingham, Massachusetts, is a biotechnology firm dedicated to developing innovative therapies for Alzheimer's disease. Founded in 2013, the company is primarily focused on its lead product, valiltramiprosate (ALZ-801), which is currently undergoing Phase 3 clinical trials. This investigational oral treatment aims to slow the progression of Alzheimer's, particularly in patients with the APOE4/4 genotype, who are at a higher risk for the disease. Alzheon has engaged in extensive research and development, supported by a significant funding history, including a recent $100 million investment. The company has also received $51 million in grants from the National Institute on Aging to support its clinical trials. Alzheon’s approach is characterized by a precision medicine strategy, targeting high-risk patients and leveraging a strong safety profile from previous studies. Their commitment to addressing unmet medical needs in Alzheimer's care positions them as a relevant player in the biotechnology sector.

10. BlueRock Therapeutics

• Website: bluerocktx.com
• Ownership type: Venture Capital
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: Canada 51%, United States (USA) 48%
• Latest funding: $1.0B, August 2019
• Founded year: 2016
• Headcount: 201-500
• LinkedIn: bluerocktx

BlueRock Therapeutics LP, founded in 2016 and based in Cambridge, Massachusetts, is a biotechnology company dedicated to developing innovative cell therapies aimed at treating degenerative diseases. The company focuses on conditions such as Parkinson's disease and inherited retinal diseases, utilizing advanced regenerative medicine techniques. BlueRock employs pluripotent stem cells to create specific cell types that can replace those lost or damaged due to disease. Their lead investigational therapy, bemdaneprocel, targets Parkinson's disease and has shown promising results in clinical trials. The company operates as a wholly-owned subsidiary of Bayer AG, which enhances its capabilities in cell and gene therapy. With a workforce of approximately 474 employees, BlueRock is positioned to make a significant impact in the biotechnology industry, particularly through its commitment to research and development and its recent funding of $1 billion in 2019.

11. MPM BioImpact

• Website: mpmcapital.com
• Ownership type: Private
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 93%, France 4%, Brazil 4%
• Founded year: 1996
• Headcount: 11-50
• LinkedIn: mpm-capital

MPM BioImpact is a biotechnology investment firm based in Boston, Massachusetts, established in 1996. The firm specializes in creating and investing in innovative companies that focus on developing transformative therapies for patients. With a robust management of over $3 billion in assets, MPM BioImpact has a proven track record, having contributed to the development of 58 FDA-approved drugs. The firm has founded 39 companies since 2010, reflecting its commitment to fostering new biotech ventures. MPM BioImpact's portfolio includes notable companies like Orna Therapeutics, which is pioneering circular RNA technology, and Aktis Oncology, which is advancing novel radiopharmaceuticals. Their investment strategy emphasizes addressing significant medical needs, making them a key player in the biotechnology sector.

12. HiFiBiO Therapeutics

• Website: hifibio.com
• Ownership type: Family Owned
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Founded year: 2013
• Headcount: 51-200
• LinkedIn: hifibio

HiFiBiO Therapeutics, founded in 2013 and based in Cambridge, Massachusetts, is a biotechnology company dedicated to developing innovative immunotherapies aimed at addressing high unmet medical needs. The company utilizes its proprietary Drug Intelligence Science (DIS®) platform, which combines advanced research methodologies with cutting-edge single-cell technology and artificial intelligence/machine learning analytics. This platform is designed to improve the understanding of cellular pathology across various diseases, facilitating target discovery, antibody selection, and predictive biomarker identification. HiFiBiO is currently advancing several clinical programs, including multiple Phase I immuno-oncology trials. The company has established partnerships with other organizations, reflecting its commitment to collaborative innovation in drug development. HiFiBiO Therapeutics is recognized for its potential to deliver transformative therapeutic solutions to patients, making it a notable player in the biotechnology industry.

13. Lfb Usa

• Website: lfb-usa.com
• Ownership type: Private
• Headquarters: Framingham, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 98%, France 2%
• Founded year: 2014
• Headcount: 51-200
• LinkedIn: lfb-usa

Lfb Usa, established in 2014 and based in Framingham, Massachusetts, is a biopharmaceutical company that specializes in the development and manufacturing of innovative therapeutic proteins aimed at treating serious and rare diseases. The company leverages its proprietary rPRO Technology™, which enhances the production process of recombinant proteins, making it more cost-effective and scalable compared to traditional methods. Lfb Usa plays a critical role in the LFB Group, a European biopharmaceutical entity, by focusing on research, clinical development, and regulatory strategies in the United States. The company is actively involved in clinical trials and has successfully brought products to market, including a recombinant form of human Factor VIIa, which has been approved by the FDA for treating hemophilia. Lfb Usa's commitment to addressing unmet medical needs through advanced biopharmaceuticals positions it as a significant player in the biotechnology industry.

14. GRO Biosciences

• Website: grobio.com
• Ownership type: Venture Capital
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $60.3M, July 2024
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: grobio

GRO Biosciences, based in Boston, Massachusetts, is a biotechnology company that specializes in protein therapeutics and synthetic biology. Founded in 2016, the company has developed a unique platform that utilizes non-standard amino acids to enhance the efficacy and safety of therapeutic proteins. Their innovative approach addresses significant challenges in the treatment of autoimmune diseases, making them a valuable partner for pharmaceutical companies and research institutions. GRO Biosciences has recently secured $60 million in Series B funding, reflecting strong investor interest and support for their mission. The company combines computational design with advanced robotics in their Biofoundry, allowing for scalable and efficient development of novel therapeutics. With a focus on reversing autoimmunity and eliminating immunogenicity, GRO Biosciences is positioned to make a meaningful impact in the biotechnology sector.

15. ROME Therapeutics

• Website: rometx.com
• Ownership type: Private Equity
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $72.0M, September 2023
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: rome-therapeutics

ROME Therapeutics, founded in 2020 and based in Boston, Massachusetts, is a biotechnology firm dedicated to pioneering new therapeutic approaches by investigating the dark genome. This underexplored segment of the human genome holds potential for groundbreaking treatments for serious diseases, particularly cancer and autoimmune disorders. ROME Therapeutics aims to leverage insights from their research to create innovative therapies that address unmet medical needs. The company has recently raised $72 million in Series B funding, reflecting strong investor interest in their mission and the potential impact of their work. Their pipeline includes a first-in-class development candidate targeting autoimmune diseases, showcasing their commitment to advancing novel therapeutic solutions. ROME Therapeutics is actively involved in the biotechnology community, co-hosting events like the Dark Genome Symposium, which fosters collaboration and knowledge sharing in this emerging field.

16. Odyssey Therapeutics

• Website: odysseytx.com
• Ownership type: Private Equity
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 78%, Germany 18%, Other 4%
• Latest funding: Series C, $101.0M, December 2023
• Founded year: 2021
• Headcount: 51-200
• LinkedIn: odyssey-tx

Odyssey Therapeutics is a biotechnology company based in Cambridge, Massachusetts, founded in 2021. The company is dedicated to discovering, developing, and commercializing innovative precision medicines aimed at treating serious diseases. Its primary focus lies in immunomodulators and oncology medicines, with a mission to transform drug discovery processes and enhance patient outcomes. Odyssey has developed a highly integrated drug hunting engine that combines traditional and emerging drug discovery technologies to target high-potential clinical and commercial opportunities, including those previously deemed 'undruggable.' The company has made significant strides in its short history, advancing multiple programs into clinical and research stages. As of December 2023, Odyssey has raised a total of $487 million in funding, with its latest Series C financing round bringing in $101 million. This financial backing supports the advancement of its therapeutic pipeline and underscores the confidence investors have in its innovative approach to drug development.

17. AI Proteins

• Website: aiproteins.bio
• Ownership type: Venture Capital
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $18.2M, November 2022
• Founded year: 2021
• Headcount: 11-50
• LinkedIn: aiproteins

AI Proteins is a biotechnology firm based in Boston, Massachusetts, established in 2021. The company specializes in the creation of innovative protein therapeutics, leveraging cutting-edge technologies such as synthetic biology and artificial intelligence. Their focus is on developing therapeutic miniproteins, which are engineered to possess ideal characteristics for drug development. AI Proteins primarily serves pharmaceutical and biotechnology companies, aiming to enhance their drug development processes. The company has identified numerous high-value therapeutic targets and is advancing its pipeline in oncology while exploring collaborations in inflammation and metabolic diseases. In November 2022, AI Proteins secured $18.2 million in funding, which supports their mission to create effective and affordable protein-based medicines. With a team of experienced professionals in protein engineering and drug development, AI Proteins is positioned to make a significant impact in the biotechnology sector.

18. Proteinea

• Website: proteinea.com
• Ownership type: Venture Capital
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: Egypt 81%, United States (USA) 11%, United Arab Emirates 4%, Other 4%
• Latest funding: Seed, June 2023
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: proteinea

Proteinea is a biotechnology firm based in Cambridge, Massachusetts, with additional labs in Cairo, Egypt, and Thuwal, Saudi Arabia. Founded in 2020, the company specializes in AI-enabled biologics design and protein engineering. Proteinea aims to revolutionize the development of therapeutic proteins and antibodies, providing solutions that enhance efficacy, safety, and convenience for biotechnology and pharmaceutical companies. Their innovative platform employs proprietary AI models and computational tools to optimize protein characteristics and streamline the experimental validation process. With a team that blends expertise from computer science, biology, and business, Proteinea is positioned to make significant contributions to the biotech industry, particularly in the area of antibody formulation and production.

19. Flare Therapeutics

• Website: flaretx.com
• Ownership type: Venture Capital
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 97%, Switzerland 3%
• Latest funding: Series B, $123.0M, March 2023
• Founded year: 2021
• Headcount: 51-200
• LinkedIn: flare-therapeutics

Flare Therapeutics is a biotechnology company based in Cambridge, Massachusetts, established in 2021. The company specializes in drug discovery with a particular emphasis on transcription factors, which are crucial in regulating gene expression. Flare's innovative approach aims to develop small molecule medicines that can effectively target these transcription factors, especially in the context of cancer treatment. Their integrated discovery engine leverages a combination of genetic, biochemical, and chemical insights to identify druggable regions within transcription factors. This strategy has led to the development of a promising pipeline, including FX-909, an investigational small molecule currently in Phase I trials for advanced urothelial cancer. In March 2023, Flare Therapeutics raised $123 million in a Series B funding round, underscoring its potential and the interest it has garnered from investors. The company primarily targets healthcare providers and pharmaceutical firms, aiming to provide advanced treatment options in precision oncology.

20. TetraGenetics Inc.

• Website: tetragenetics.com
• Ownership type: Corporate
• Headquarters: Arlington, Massachusetts, United States (USA)
• Latest funding: September 2021
• Founded year: 2004
• Headcount: 11-50
• LinkedIn: tetragenetics-inc.

TetraGenetics Inc. is a biotechnology firm based in Arlington, Massachusetts, founded in 2004. The company specializes in the discovery and development of antibody medicines, focusing on innovative therapies for diseases such as cancer and autoimmune disorders. TetraGenetics collaborates with various pharmaceutical and biotech companies, leveraging advanced technologies to streamline drug development processes. Their commitment to creating effective therapies is evident in their strategic partnerships and ongoing research initiatives. Although there is no recent funding reported, their active engagement in the biotechnology sector and their focus on addressing unmet medical needs highlight their significance in the industry.

21. MedTherapy Biotech

• Website: medtherapybiotech.com
• Ownership type: Private
• Headquarters: Quincy, Massachusetts, United States (USA)
• Employee distribution: India 76%, United States (USA) 24%
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: medtherapy

MedTherapy Biotech is a biotechnology company based in Quincy, Massachusetts, founded in 2018 by experts from Harvard and former Novartis executives. The company specializes in cancer cell and gene therapies, focusing on CAR-T cell therapies and viral vectors. MedTherapy provides comprehensive services, including the manufacturing of these therapies, regulatory support, and analytical services. Their facilities in Boston, USA, and New Delhi, India, enable them to operate on a global scale, catering to pharmaceutical companies and research institutions. MedTherapy aims to address the high costs and complexities associated with cancer gene therapies, striving to make these treatments more accessible to patients worldwide. Their innovative technologies significantly reduce manufacturing time and costs, positioning them as a valuable partner in the biotechnology sector.

22. Photys Therapeutics

• Website: photys.com
• Ownership type: Venture Capital
• Headquarters: Waltham, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $75.0M, September 2022
• Founded year: 2021
• Headcount: 11-50
• LinkedIn: photys

Photys Therapeutics, based in Waltham, Massachusetts, is a biotechnology company that specializes in developing innovative therapeutic solutions through its proprietary bifunctional small molecules platform. Founded in 2021, the company is dedicated to precision phosphorylation, a process that modulates and repairs proteins associated with various diseases. This focus caters primarily to pharmaceutical companies and research institutions that require advanced drug development technologies. Photys has garnered attention in the industry, evidenced by its successful Series A funding round, which raised $75 million in September 2022. The company was co-founded by a prominent chemist from the Broad Institute, Amit Choudhary, and is supported by a scientific advisory board that includes distinguished scientists and drug developers from prestigious institutions. This combination of innovative technology and expert guidance positions Photys Therapeutics as a noteworthy entity in the biotechnology sector.

23. LG Chem Life Sciences USA, Inc.

• Website: innovation.lgchem.com
• Ownership type: Private
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: South Korea 60%, United States (USA) 40%
• Founded year: 2019
• Headcount: 51-200
• LinkedIn: lg-chem-life-sciences-innovation-center

LG Chem Life Sciences USA, Inc. is a biotechnology company based in Boston, Massachusetts, specializing in pharmaceuticals and innovative drug development. Established in 2019, the firm is dedicated to conducting research and clinical trials to develop effective treatments for serious health conditions. Their operations include a strong pipeline of drug candidates, reflecting their commitment to advancing medical science. The company primarily serves healthcare providers and research institutions, indicating a focus on collaboration within the healthcare ecosystem. With a workforce that is split between South Korea and the United States, LG Chem Life Sciences USA is positioned to leverage global expertise in its research endeavors.

24. Cugene Inc.

• Website: cugene.com
• Ownership type: Private
• Headquarters: Waltham, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: cugene

Cugene Inc., based in Waltham, Massachusetts, is a clinical-stage biotechnology company founded in 2016. The company specializes in developing next-generation precision immunology and oncology medicines. Cugene's research is centered on creating novel therapeutic solutions that target specific immune cells, aiming to enhance treatment efficacy for autoimmune diseases and cancer. Their innovative approach involves precision molecular engineering to design molecules that promote immune tolerance and selectively target cancer cells, minimizing off-target effects. Cugene collaborates with healthcare providers and pharmaceutical firms to address significant medical needs, showcasing their commitment to advancing biomedicine. The company is also focused on building a collaborative culture to attract top talent, which is essential for their growth and innovation in the competitive biotech landscape.

Biotechnology Insights: Key Companies in Massachusetts

Want to Find More Biotechnology Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!